-
Here's why regenerative medicine needs more research in sports medicine, 1 surgeon says
The consensus on whether regenerative medicine is effective in sports medicine is still up in the air, according to Michael Ciccotti, MD, of Rothman Orthopaedic Institute in Philadelphia. -
At least 2 deaths linked to tainted bone graft
A Michigan woman died from tuberculosis linked to tainted bone graft, The Detroit News reported Aug, 18. -
Aziyo Biologics looking to divest orthopedic business
Aziyo Biologics is in talks to divest its orthopedic business, the company said Aug. 14. -
5 orthobiologics updates
Here are five developments in orthopedic regenerative medicine since July 11. -
Dr. Ken Zaslav debuts Agili-C implant in the US
Orthopedic surgeon Ken Zaslav, MD, performed the first commercial case with CartiHeal's Agili-C in the U.S., the medtech company said July 26. -
CDC investigating tuberculosis infections linked to recalled bone grafts
The CDC and FDA are investigating an outbreak of tuberculosis linked to recently recalled viable bone matrix material. -
'Color me skeptical': Orthobiologics' place in medicine
Ronald Hillock, MD, an adult joint reconstruction surgeon and musculoskeletal oncologist at Nevada Orthopedic & Spine Center in Las Vegas, connected with Becker's to answer, "Are orthobiologics overhyped?" -
Are orthobiologics overhyped?
Gurtej Singh, MD, a physical medicine and rehabilitation physician, connected with Becker's to answer, "Are orthobiologics overhyped?" -
Aziyo Biologics voluntarily recalls viable bone matrix products
Aziyo Biologics is recalling its viable bone matrix products after two patients were infected with Mycobacterium tuberculosis following surgeries, the orthobiologics company said July 13. -
First cases with EnFix RC fiber implant completed
The first four surgeries using the EnFix RC fiber implant for rotator cuff repair were completed at Rush Oak Brook (Ill.) Surgery Center. -
Biden administration launches program focused on orthobiologics
The Biden administration launched a program under the Advanced Research Projects Agency for Health focused on orthopedic tissue regeneration. -
5 developments in orthobiologics
Here are five developments in orthobiologics to know since April 1: -
Royal Biologics launches new bone graft substitute
Royal Biologics launched its Bio-Reign 3D bone graft substitute, the company said May 23. -
Study supports efficacy of StemSpine procedure
Creative Medical Technology Holdings' StemSpine procedure was found to be effective in treating chronic lower back pain, according to a pilot study. -
Bioventus sells wound care segment
Bioventus sold its wound care segment to LifeNet Health, according to a May 10 news release. -
1,000 patients treated with OssDesign spinal bone graft
OssDesign's Catalyst nanosynthetic bone graft has been used in 1,000 patients, the medtech company said May 9. -
Bioventus CEO steps down
Bioventus' CEO Ken Reali left his post on April 4. -
University of Colorado Medicine opens regenerative orthopedic center
Aurora-based University of Colorado Medicine opened the CU Medicine Regenerative Medicine, Hand and Spine Center in Englewood. -
5 orthobiologics updates in Q1
Here are five updates in orthobiologics and regenerative medicine to know from the first quarter of 2023: -
Minimally invasive cellular allograft system cleared for use in trauma procedures
The world's first viable bone matrix that provides lineage-committed bone cells, LifeNet Health's ViviGen MIS, is now available for use in trauma procedures.
Page 5 of 37